Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)
Paul Hudson predicts delayed impact on Sanofi from Biden's IRA, as Dupixent beats last quarter's sales
As third quarter numbers rolled in, Sanofi CEO Paul Hudson alluded to the French pharma’s objectives moving forward.
Kicking off a call Friday morning with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
